Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 607

1.

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group..

Gastroenterology. 2007 May;132(5):1672-83.

PMID:
17484865
2.

Natalizumab for active Crohn's disease.

Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnálek P, Zádorová Z, Palmer T, Donoghue S; Natalizumab Pan-European Study Group..

N Engl J Med. 2003 Jan 2;348(1):24-32.

3.

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, Donoghue S, Greenlees C, Subhani J, Amlot PL, Pounder RE.

Gastroenterology. 2001 Aug;121(2):268-74.

PMID:
11487536
4.
5.

Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.

Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, Katz S, Goldblum R, Harrigan R, Hilton D, Hanauer SB.

Inflamm Bowel Dis. 2007 Jan;13(1):2-11.

PMID:
17206633
6.

Natalizumab for induction of remission in Crohn's disease.

Macdonald JK, McDonald JW.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD006097. Review. Update in: Cochrane Database Syst Rev. 2007;(1):CD006097.

PMID:
16856112
7.

Natalizumab for induction of remission in Crohn's disease.

MacDonald JK, McDonald JW.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006097. Review.

PMID:
17253580
8.

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R; REACH Study Group..

Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6.

PMID:
17324398
9.

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.

Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB.

Aliment Pharmacol Ther. 2005 Feb 15;21(4):373-84.

10.

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.

Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zákuciová M, D'Haens G, Van Assche G, Ba S, Lee S, Pearce T.

Gut. 2006 Aug;55(8):1131-7.

11.

CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Feagan BG, Sandborn WJ, Lichtenstein G, Radford-Smith G, Patel J, Innes A.

Aliment Pharmacol Ther. 2006 Mar 1;23(5):617-28.

12.

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ.

Gastroenterology. 1999 Oct;117(4):761-9.

PMID:
10500056
13.

Anti-interleukin-12 antibody for active Crohn's disease.

Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W; Anti-IL-12 Crohn's Disease Study Group..

N Engl J Med. 2004 Nov 11;351(20):2069-79. Erratum in: N Engl J Med. 2005 Mar 24;352(12):1276. Yang, Zhiqiong [added].

14.

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ.

N Engl J Med. 1997 Oct 9;337(15):1029-35.

15.

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR.

Gastroenterology. 2001 Nov;121(5):1088-94.

PMID:
11677200
16.

Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Schreiber S, Feagan B, D'Haens G, Colombel JF, Geboes K, Yurcov M, Isakov V, Golovenko O, Bernstein CN, Ludwig D, Winter T, Meier U, Yong C, Steffgen J; BIRB 796 Study Group..

Clin Gastroenterol Hepatol. 2006 Mar;4(3):325-34.

PMID:
16527696
17.

Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.

Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, Tami J, Dorr FA, Sewell KL.

Aliment Pharmacol Ther. 2002 Oct;16(10):1761-70.

18.

Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.

Thia KT, Sandborn WJ, Lewis JD, Loftus EV Jr, Feagan BG, Steinhart AH, Hanauer SB, Persson T, Sands BE.

Am J Gastroenterol. 2008 Dec;103(12):3123-31. doi: 10.1111/j.1572-0241.2008.02176.x.

PMID:
18786111
19.

Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy.

Dudley-Brown S, Nag A, Cullinan C, Ayers M, Hass S, Panjabi S.

Gastroenterol Nurs. 2009 Sep-Oct;32(5):327-39. doi: 10.1097/SGA.0b013e3181bb1484.

PMID:
19820441
20.

Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group.

Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, Hanauer SB, McDonald JW, Feagan BG, Fedorak RN, Isaacs KL, Pike MG, Mays DC, Lipsky JJ, Gordon S, Kleoudis CS, Murdock RH Jr.

Gastroenterology. 1999 Sep;117(3):527-35.

PMID:
10464128
Items per page

Supplemental Content

Support Center